Montefiore Medical Center - Weiler campus (Site 206-003)
Welcome,         Profile    Billing    Logout  
 0 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ICC, Washington DC
NCT05822583: Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial

Recruiting
4
1500
Europe, US, RoW
abatacept infusion, Placebo group
University of Minnesota
COVID-19
07/25
07/25
INSIGHT12, NCT04910269: Outpatient Treatment With Anti-Coronavirus Immunoglobulin

Recruiting
3
820
Europe, US, RoW
Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo
University of Minnesota, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)
COVID, SARS-CoV2 Infection, Covid19
08/24
08/24
NCT05605093: Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)

Recruiting
3
1500
Europe, Japan, US, RoW
Shionogi Protease Inhibitor (S-217622), ensitrelvir, placebo
University of Minnesota, National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
07/25
07/25
ICC, Nashville
NCT05822583: Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial

Recruiting
4
1500
Europe, US, RoW
abatacept infusion, Placebo group
University of Minnesota
COVID-19
07/25
07/25
NCT05605093: Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)

Recruiting
3
1500
Europe, Japan, US, RoW
Shionogi Protease Inhibitor (S-217622), ensitrelvir, placebo
University of Minnesota, National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
07/25
07/25
ICC, Hennepin
NCT05822583: Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial

Recruiting
4
1500
Europe, US, RoW
abatacept infusion, Placebo group
University of Minnesota
COVID-19
07/25
07/25
NCT05605093: Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)

Recruiting
3
1500
Europe, Japan, US, RoW
Shionogi Protease Inhibitor (S-217622), ensitrelvir, placebo
University of Minnesota, National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
07/25
07/25
ICC, New York
NCT05822583: Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial

Recruiting
4
1500
Europe, US, RoW
abatacept infusion, Placebo group
University of Minnesota
COVID-19
07/25
07/25
NCT05605093: Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)

Recruiting
3
1500
Europe, Japan, US, RoW
Shionogi Protease Inhibitor (S-217622), ensitrelvir, placebo
University of Minnesota, National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
07/25
07/25

Download Options